Genomill Health — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Genomill Health is a private, pre-revenue diagnostics company developing a streamlined NGS technology platform. Its core innovations, the Geno1® library prep system with Bridge Capture™ and Nicking Loop™, aim to significantly reduce the complexity, time, and cost of sensitive genomic testing, with a focus on liquid biopsy and minimal residual disease monitoring in cancer. The company is generating early validation data and media recognition, positioning its technology for future clinical adoption and commercialization.

Oncology

Technology Platform

Geno1® system featuring PCR-free, early-indexed library prep with Bridge Capture™ (targeted enrichment) and Nicking Loop™ (platform-agnostic sequencing) technologies. Focus on ultra-sensitive, rapid, low-cost, and simple NGS workflows for diagnostics.

Opportunities

The rapid growth of liquid biopsy and decentralized genomic testing creates demand for simpler, cheaper, and more sensitive NGS workflows.

Genomill's technology could capture market share by enabling more labs to perform high-performance sequencing without major infrastructure investments.

Risk Factors

The company faces significant competition from entrenched market leaders and must complete extensive clinical validation to gain regulatory approval and market trust.

As a pre-revenue startup, it is also dependent on securing ongoing investment to fund commercialization efforts.

Competitive Landscape

Genomill competes in the NGS sample preparation market against large, established players like Illumina, Thermo Fisher Scientific, and Roche, who offer comprehensive but often complex and expensive workflows. Its differentiation lies in a simplified, cost-reduced, and sensitive platform designed for accessibility.

More companies in Diagnostics & Precision Medicine →More companies in Finland →